







Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy

Jeremy R. Tietjens, MD; David Claman, MD; Eric J. Kezirian, MD, MPH; Teresa De Marco, MD; Armen Mirzayan, DDS; Bijan Sadroonri, MD; Andrew N. Goldberg, MD; Carlin Long, MD; Edward P. Gerstenfeld, MD; Yerem Yeghiazarians, MD

ardiovascular disease (CVD) remains a highly prevalent scause of morbidity and mortality, both in the United States and worldwide. In parallel with the development of new and improved therapies for established CVD such as coronary artery disease or heart failure (IRI), there has been an increased focus on modification of cardiovascular risk factors for both primary and secondary prevention, reflecting an evolving understanding of CVD as a systemic process with numerous determinants.


Obstructive sleep apnea (OSA) has been associated with

remains controversial, as randomized trials performed to date remain limited in number as well as design, highlighting the need for further study. Furthermore, the current literature suggests that the impact of diagnosing and treating OSA varies between specific CVD processes, implying the need for a more sophisticated understanding and nuanced clinical approach to this issue. In this article we review the literature pertaining to OSA in patients with CVD. Additionally, we offer a practical clinical approach to the evaluation and management of known or suspected OSA in patients with CVD.

Table 4. Overview of Surgical Procedures for Obstructive Sleep Apnea

Anatomic Region	Specific Procedures	Outcomes
Nasal	Turbinate reduction Septoplasty Nasal valve surgery Rhinoplasty Nasal polypectomy Adenoidectomy	Significant 2.66 cm Hyb reduction in required CPPP pressure (95% 0.1.57-3.65; A-0.0001) reports in mate-analysis showing pasts surprised? Average nightly CPAP use increased from 3.0::3.1 h preoperatively to 5.5±2.0 h follows surgify
Upper pharyngeal	Uvulopalatopharyngoplasty Uvulopalatal flap Several other variants of UPPP are used Tonsillectomy	Pooled polysomographic success rate 50% for UPP9 in meta-analyses; however, results from individual studies vary significantly, with success rates up to 83% in more selectificants.
Lower pharyngeal	Tongue reduction procedures Tongue advancement/stabilization procedures Epiglottis procedures	Polysomnographic success rate ranges from 35% to 62% across studies of various hypopharyngeal procedures ⁶⁸
Global upper airway procedures	Maxillomandibular advancement Tracheotomy Upper airway stimulation	Pooles efficacy results from metis-analyses of each procedure type: - MMA: 98% souces rater and 45% cur enter ¹⁶⁹ - Tracheotromy: significant reduction in AH by mean 79.82 events/h (95% CI 63.7-95. A-0.000) ¹⁶⁹ - Proposass attimulation: significant reduction in AH by mean 17.51 events/h (95% CI 63.7-95. A-0.000) ¹⁶⁹ - Proposass attimulation: significant reduction in AH by mean 17.51 events/h (95% CI 63.7-4.5) ²⁷














Fixture Position

Compressive Strength C-Factor Wear Resistance Compatibility Tensile Strength







Prosthetically Driven	
Implant Placement	
Prosthetically and	
Surgically Balanced Implant Placement	
Biomimetic Implant Therapy	











































































































Surgical Stent Design
































Surgical Access














Keys and Handles



























Drill name	Guided length	Overall length	Symbol for drill length
Short	16.0 mm	32.0 mm	-
Long	20.0 mm	36.0 mm	=
Extra-long	24.0 mm	40.0 mm	=
Ovi	erall length	Symbol for drill lens	gth.

